Vistusertib

Drug Profile

Vistusertib

Alternative Names: AZD 2014

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Meningioma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase I/II Breast cancer; Fallopian tube cancer; Glioblastoma; Peritoneal cancer
  • Phase I Prostate cancer
  • No development reported Advanced breast cancer
  • Discontinued Renal cancer

Most Recent Events

  • 13 Apr 2017 Samsung Medical Center and AstraZeneca plan the SUKSES-D phase III trial for Small cell lung cancer (Monotherapy)(NCT03106155)
  • 09 Mar 2017 Massachusetts General Hospital, National Cancer Institute and AstraZeneca plan a phase II trial for Meningioma (Recurrent; Second-line therapy or greater) in USA (NCT03071874)
  • 01 Feb 2017 Samsung Medical Center initiates enrolment in a phase II trial for Gastric cancer (Second-line therapy or greater) in South Korea (NCT03082833)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top